HBT Labs, Inc.

Strategic Acquisition Strengthens American Regent's Pipeline and Expansion in the U.S. SHIRLEY, N.Y. , Aug. 17, 2022 /PRNewswire/ -- American Regent, Inc., a U.S. manufacturer of pharmaceuticals for human and veterinary use with manufacturing sites in New York and Ohio, today announced it acquired HBT Labs, Inc. based in California. HBT Labs has a pipeline of generic and 505(b)(2) pharmaceutical products that target various treatment indications including cancer and Central Nervous System (CNS) disorders. Continue Reading "Our acquisition of HBT Labs supports our growing product portfolio, efforts to expand into the oncology market, and dedication to better meeting the needs of providers and patients," said Paul Diolosa, President and CEO of American Regent. "HBT's proprietary processes and technologies to produce complex drugs will enable us to achieve our business objectives of applying innovative thinking to respond to customer needs. We look forward to working with the management team and respected staff of HBT, who are leaders in highly specialized drugs and delivery systems." Strategic Acquisition Strengthens American Regent's Pipeline and Expansion in the U.S. Tweet this With the acquisition, American Regent will support the existing commercialization of HBT's authorized generic that is managed through a partner, in addition to supporting the launch of HBT's FDA approved 505(b)(2) New Drug Application (NDA) providing for the use of Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound), lyophilized powder for reconstitution, 100 mg/vial. HBT Labs, Inc. will function as a wholly owned subsidiary of American Regent, Inc., and will continue research and development and commercial operations in Brea, California. American Regent financed the transaction with existing cash on hand. About American Regent, Inc. American Regent, Inc., a Daiichi Sankyo Group company, is a leading injectable manufacturer. For over 50 years, American Regent has been developing, manufacturing, and supplying quality generic and branded injectables for healthcare providers. For nearly 20 years, we have been a leader in IV iron therapy. American Regent is committed to U.S.-based manufacturing. To that end, over the last several years, we have made significant investments in expanding and modernizing our manufacturing facilities in Ohio and New York. This expansion will nearly double our capacity and allow us to better serve our customers now and in the future. Speed counts. Flexibility matters. Reliability and quality are paramount. Because patients should never have to wait for the medications they need. For more information, please visit . SOURCE American Regent, Inc.

JERSEY CITY, N.J., June 7, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of market assessment report on "Global SERD Therapeutics Market (Products (Faslodex, RAD1901, GDC-9545, AZD9833, SAR439859, and Other Generics), Therapy (First-Line Treatment, Second-Line Treatment))– Industry Analysis, Competitive Landscape, Revenue Forecast 2020-2030" According to the latest research by InsightAce Analytic, the global SERD therapeutics market size valued at US$ 1.33 billion, and it is expected to reach US$ 5.75 billion in 2030, recording a promising CAGR of 17.9% during the period of 2020-2030. Selective estrogen receptor degrader (SERD) is a type of drug which downregulates the estrogen receptor. SERD and full receptor antagonist are essential treatment options for HR-positive breast cancer. Tamoxifen, a particular estrogen receptor modulator (SERM) with receptor agonist and antagonist action, and aromatase inhibitors, which prevent estrogen production, but cause acquired resistance, are examples of endocrine medicines. Fulvestrant, the only SERD currently licensed, has weak drug-like characteristics. The development of oral SERDs with optimal target occupancy and potency and enhanced clinical performance has been a primary emphasis for improving disease management. The increasing investments by key players in the development of promising breast cancer therapies are anticipated to fuel the SERD therapeutics market growth over the forecast period. Request for Sample Pages: Major driving factors in the SERD therapeutics market are the increasing need for SERD therapies, the high prevalence of breast cancer, rising number of clinical trials. Furthermore, the fast adoption of advanced medical technologies, population growth, and a growing number of health-conscious people will enhance the growth of the SERD therapeutics market. However, the high price of devices, complex procedures, and resistance to endocrine therapy is restraining the development of this market. Moreover, the COVID-19 pandemic has both positively and negatively impacted the SERD therapeutics market due to the lockdown situations. At the regional level, the North American region is the major revenue holder of this market due to rising awareness about SERD therapies, increasing government investments in the research and development of therapies for the treatment of various cancer diseases, and the rising prevalence of breast cancer. On the other hand, the Europe region will also dominate the market during the forecast period due to the advancements in the biopharmaceutical field, stringent regulations, and the increasing prevalence of chronic diseases. The Asia-Pacific market is projected to show significant growth in the future due to the growing SERD therapeutic industries and fast adaption of new technologies. Enquiry Before Buy: Leading manufacturers in this field are focusing on novel SERD therapy innovations, making new partnerships, collaborations and agreements, growing awareness about SERD therapies, and increasing research investments for developing advanced technologies. These strategies will propel their growth opportunities in the market. In 2020, QLHC announced an evaluation of Sanofi's SAR439859, an oral estrogen receptor degrader (SERD), in a new I-SPY 2 study arm targeting patients with newly diagnosed hormone receptor-positive (HR+) clinical stage 2/3 invasive breast cancer. AstraZeneca moved its next-generation oral SERD AZD9833 into phase 1 in 2018. While work on AZD9496 stalled after a few early clinical trials, AstraZeneca has quickly expanded and advanced the development of AZD9833. Late last month, AstraZeneca began enrolling patients in the phase 3 clinical trial of AZD9833. Major key Players in the SERD therapeutics market are Amneal Pharmaceuticals Inc, AstraZeneca, Plc., Dr Reddy's Laboratories, Eli Lilly and Company, G1 Therapeutics, Inc., Glenmark Pharmaceuticals, HBT Labs, Inc, Hoffmann-La Roche AG, InventisBio, Novartis AG, Radius Health, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Zenopharm LLC., Zentalis Pharmaceuticals, and List of Other Prominent Players. Recent Key Developments: In June 2021, Eli Lilly and Company presented new results for the exploratory use of Verzenio® (abemaciclib) in high-risk early breast cancer, as well as for its oral selective oestrogen receptor degrader (SERD) LY3484356 (ASCO). Lilly is releasing an exploratory analysis from the positive Phase 3 monarch study testing Verzenio, a CDK4/6 inhibitor, in a subset of patients with HR+, HER2-, high-risk early breast cancer (EBC) who had had neoadjuvant chemotherapy. In Sept 2020, InventisBio recently announced the conclusion of a $147 million series D fundraising, which included several of the world's leading biopharmaceutical and healthcare venture capital firms. InventisBio currently has three medicinal compounds in various stages of clinical development, and one new product has recently begun a worldwide phase I clinical trial. D-0502 showed remarkable anti-tumour effectiveness in phase 1 research, with superior absorption and an acceptable safety profile when compared to other oral SERDs in clinical development throughout the world. In Sept 2019, Preliminary data from a Phase 1/2a dose-escalation trial of G1T48, an oral selective oestrogen receptor degrader (SERD), in patients with oestrogen receptor-positive, HER2-negative (ER+, HER2-) breast cancer were released by G1 Therapeutics, Inc. G1T48 was well tolerated in the study and showed anti-tumour effectiveness in patients who had been substantially pre-treated. The results of this trial support the future development of G1T48 in both first line and adjuvant settings, and a first-line Phase 3 pivotal trial is expected to begin in 2020. Market Segments Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on Products Faslodex RAD1901 GDC-9545 AZD9833 SAR439859 Other Generics Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on Therapy First-Line Treatment Second-Line Treatment Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on Region North America Europe Asia Pacific Latin America Middle East & Africa North America SERD therapeutics market revenue (US$ Million) by Country, 2020 to 2030 U.S. Canada Europe SERD therapeutics market revenue (US$ Million) by Country, 2020 to 2030 Germany France Italy Spain Russia Rest of Europe Asia Pacific SERD therapeutics market revenue (US$ Million) by Country, 2020 to 2030 India China Japan South Korea Australia & New Zealand Latin America SERD therapeutics market revenue (US$ Million) by Country, 2020 to 2030 Brazil Mexico Rest of Latin America Middle East & Africa SERD therapeutics market revenue (US$ Million) by Country, 2020 to 2030 GCC Countries South Africa Rest of Middle East & Africa Why should buy this report: To receive a comprehensive analysis of the prospects for global SERD therapeutics market To receive industry overview and future trends of global SERD therapeutics market To analyse the SERD therapeutics market drivers and challenges To get information on SERD therapeutics market size value (US$ Mn) forecast till 2030 Major Investments, Mergers & Acquisition in global SERD therapeutics market industry For Customization @ Other Related Reports Published by InsightAce Analytic: Global RNA-based Therapeutics Market Global Stem Cell Exosome Therapeutic Market Global Antisense Oligonucleotide Therapeutics Market Global Oncolytic Virus Therapy Market Global Immuno-Oncology Cell Therapy Market About Us: InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner. Contact Us: InsightAce Analytic Pvt. Ltd. Tel.: +1 718 593 4405 Email: [email protected] Site Visit: Follow Us on LinkedIn @ bit.ly/2tBXsgS Follow Us On Facebook @ bit.ly/2H9jnDZ SOURCE InsightAce Analytic Pvt. Ltd.